153154-43-9

Upstream product

• 18162-48-6 tert-butyldimethylsilyl chloride 
• 1078691-95-8 (+)-D-glucosamine hydrochloride 
• 1125-88-8 benzaldehyde dimethyl acetal 
• 99049-67-9 tert-Butyldimethylsilyl-2-azido-2-desoxy-β-D-glucopyranosid 

Downstream Products

• 937394-24-6 t-butyldimethylsilyl 3-O-allyloxycarbonyl-6-O-benzyl-2-deoxy-4-O-(1,5-dihydro-3-oxo-3λ⁵-3H-2,4,3-benzodioxaphosphepin-3yl)-2-(9-fluorenylmethoxycarbonylamino)-β-D-glucopyranoside 
• 937394-56-4 C₄₄H₅₉N₄O₁₄PSi 
• 937394-26-8 tert-butyldimethylsilyl-6-O-[3-O-allyloxycarbonyl-6-O-benzyl-2-deoxy-4-O-(1,5-dihydro-3-oxo-3λ⁵-3H-2,4,3-benzodioxaphosphepin-3-yl)-2-(9-fluorenylmethoxycarbonylamino)-β-D-glucopyranosyl]-2-azido-4-O-benzyl-2-deoxy-β-D-glucopyranoside 
• 937394-21-3 tert-butyldimethylsilyl 2-azido-4-O-benzyl-2-deoxy-β-D-glucopyranoside 
• 937394-22-4 tert-butyldimethylsilyl 3-O-allyloxycarbonyl-2-azido-6-O-benzyl-2-deoxy-β-D-glucopyranoside 
• 937394-23-5 t-butyldimethylsilyl 3-O-allyloxycarbonyl-2-azido-6-O-benzyl-2-deoxy-4-O-(1,5-dihydro-3-oxo-3λ⁵-3H-2,4,3-benzodioxaphosphepin-3yl)-β-D-glucopyranoside 
• 144674-59-9 tert-butyldimethylsilyl O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-(1->4)-<(2,3,4-tri-O-benzyl-α-L-fucopyranosyl)-(1->3)>-2-azido-6-O-benzyl-2-deoxy-β-D-glucopyranoside 
• 144674-58-8 tert-butyldimethylsilyl O-(2,3,4,-tri-O-benzyl-α-L-fucopyranosyl)-(1->3)-2-azido-6-O-benzyl-2-deoxy-β-D-glucopyranoside 

Relevant academic research and scientific papers

A concise synthesis of tetrahydroxy-LCB, α-galactosyl ceramide, and 1,4-dideoxy-1,4-imino-L-ribitol via D-allosamines as key building blocks

The total syntheses of tetrahydroxy-LCB 1, α-galactosyl ceramide 2, and 1,4-dideoxy-1,4-imino-L-ribitol 3 via D-allosamine derivatives as common synthons are described here.

SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS

PROBLEM TO BE SOLVED: To provide a novel glucopyranosyl lipid adjuvant (GLA) for inducing or enhancing immune responses, and a vaccine composition and a pharmaceutical composition comprising the GLA. SOLUTION: The present invention provides a GLA represented by a compound of the following formula, and a vaccine composition and a pharmaceutical composition comprising the GLA. SELECTED DRAWING: None COPYRIGHT: (C)2016,JPOandINPIT

Solid- and solution-phase synthesis of heparin and other glycosaminoglycans

Described is a modular, general synthetic strategy for the preparation in solution and on a solid support of heparin, heparin-like glycosaminoglycans, glycosaminoglycans and non-natural analogs of each of them. Additionally, the modular strategy provides

Glycosyl Imidates, 65. Efficient Synthesis of the Lewis Antigen X (Lex) Family

tert-Butyldimethylsilyl 2-azido-4,6-O-benzylideneglucopyranoside 5 proved to be a versatile starting material for the synthesis of the Lex antigen family. 3-O-Fucosylation of 5, ensuing reductive benzylidene ring cleavage, and then 4-O-galactos